{"entity":{"id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","aka":[],"tldr":"A phase 1/2 trial of Dose Level 1, VNX-202 in advanced solid tumours, run by Vironexis Biotherapeutics Inc., now recruiting.","summary":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2) is a phase 1/2 interventional study registered as NCT07192432 by Vironexis Biotherapeutics Inc., with 27 participants planned, started 2025-11-18 and due to reach its primary completion in 2033-09. Interventions recorded: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202 and Dose Level 4, VNX-202.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07192432","url":"https://clinicaltrials.gov/study/NCT07192432"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07192432","phase":"1/2","setting":"A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer","sponsor":"Vironexis Biotherapeutics Inc.","enrolled":27,"outcomes":[]},"route":"/trials/nct07192432/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}